[{"id":"33da474f-b112-4a34-ad2b-bf3aa8c54e06","acronym":"AALL1231","url":"https://clinicaltrials.gov/study/NCT02112916","created_at":"2021-01-18T09:46:35.591Z","updated_at":"2025-02-25T16:51:23.270Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT02112916 - AALL1231","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 847","initiation":"Initiation: 10/04/2014","start_date":" 10/04/2014","primary_txt":" Primary completion: 03/31/2020","primary_completion_date":" 03/31/2020","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-04"},{"id":"a5f14953-ab61-4581-b513-a86ad8a1e2b8","acronym":"AALL0434","url":"https://clinicaltrials.gov/study/NCT00408005","created_at":"2021-01-17T17:29:32.376Z","updated_at":"2025-02-25T16:50:52.092Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT00408005 - AALL0434","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1895","initiation":"Initiation: 01/22/2007","start_date":" 01/22/2007","primary_txt":" Primary completion: 09/30/2017","primary_completion_date":" 09/30/2017","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-04"},{"id":"2fd1f36d-538c-4925-82be-67b0b08c4340","acronym":"","url":"https://clinicaltrials.gov/study/NCT04301076","created_at":"2021-01-18T20:51:47.723Z","updated_at":"2024-07-02T16:35:16.189Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATL)","source_id_and_acronym":"NCT04301076","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4 • CD2","pipe":"","alterations":" ","tags":["CD4 • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/31/2021","start_date":" 08/31/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-06"},{"id":"e1f4b5d9-cd5a-47dd-995e-7ea37a995e84","acronym":"","url":"https://clinicaltrials.gov/study/NCT05464836","created_at":"2022-07-19T14:54:34.934Z","updated_at":"2024-07-02T16:35:19.865Z","phase":"Phase 2","brief_title":"Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL","source_id_and_acronym":"NCT05464836","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2 • CD8 • CD34 • CD5 • CD7 • CD2","pipe":"","alterations":" ","tags":["BCL2 • CD8 • CD34 • CD5 • CD7 • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • limantrafin (CB-103)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/06/2023","start_date":" 04/06/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-02-12"},{"id":"5206abc5-f3bf-41df-978b-3fe0011087ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT05504408","created_at":"2022-08-17T13:55:03.907Z","updated_at":"2024-07-02T16:35:34.127Z","phase":"","brief_title":"Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia","source_id_and_acronym":"NCT05504408","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" TNFRSF8 • IL2RA • CD2 • ISG20","pipe":" | ","alterations":" TNFRSF8 expression • IL2RA expression","tags":["TNFRSF8 • IL2RA • CD2 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • IL2RA expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2023-10-10"},{"id":"a06f8976-07ab-403a-b4d1-63d88700423a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00074282","created_at":"2021-01-18T00:11:47.065Z","updated_at":"2024-07-02T16:35:44.331Z","phase":"Phase 2","brief_title":"Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL","source_id_and_acronym":"NCT00074282","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" CD5 • CD2","pipe":"","alterations":" ","tags":["CD5 • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Campath (alemtuzumab) • pentostatin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 102","initiation":"Initiation: 04/14/2005","start_date":" 04/14/2005","primary_txt":" Primary completion: 12/09/2017","primary_completion_date":" 12/09/2017","study_txt":" Completion: 05/06/2018","study_completion_date":" 05/06/2018","last_update_posted":"2023-06-29"},{"id":"8a68b3a6-5618-4bd8-8234-f0a6ac6765e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01723839","created_at":"2021-01-18T07:31:35.969Z","updated_at":"2025-02-25T14:33:48.664Z","phase":"Phase 2","brief_title":"Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide","source_id_and_acronym":"NCT01723839","lead_sponsor":"Hackensack Meridian Health","biomarkers":" CD20 • CD5 • CD2","pipe":"","alterations":" ","tags":["CD20 • CD5 • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • cyclophosphamide • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 02/22/2012","start_date":" 02/22/2012","primary_txt":" Primary completion: 06/08/2021","primary_completion_date":" 06/08/2021","study_txt":" Completion: 06/08/2021","study_completion_date":" 06/08/2021","last_update_posted":"2022-10-10"},{"id":"45027f83-3b0a-45d5-b618-4e8c0da85c7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01445535","created_at":"2021-01-18T05:59:48.054Z","updated_at":"2024-07-02T16:36:21.558Z","phase":"Phase 1","brief_title":"Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas","source_id_and_acronym":"NCT01445535","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • CD2","pipe":" | ","alterations":" ALK positive","tags":["ALK • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Marqibo (vincristine liposomal) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 01/13/2009","start_date":" 01/13/2009","primary_txt":" Primary completion: 04/01/2011","primary_completion_date":" 04/01/2011","study_txt":" Completion: 10/22/2020","study_completion_date":" 10/22/2020","last_update_posted":"2021-11-03"},{"id":"8f61df51-bc1b-4204-bd31-0fe890833aeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00858117","created_at":"2021-01-18T03:16:13.555Z","updated_at":"2025-02-25T17:17:10.767Z","phase":"Phase 2","brief_title":"A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL","source_id_and_acronym":"NCT00858117","lead_sponsor":"Northwestern University","biomarkers":" CD20 • CD5 • CD52 • CD2","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • CD5 • CD52 • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Campath (alemtuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 09/26/2005","start_date":" 09/26/2005","primary_txt":" Primary completion: 03/17/2010","primary_completion_date":" 03/17/2010","study_txt":" Completion: 01/24/2013","study_completion_date":" 01/24/2013","last_update_posted":"2020-11-06"}]